Bio-Techne Corp

TECH Healthcare Biotechnology

Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025. In the quarter to June 2026, revenue grew 1.33%, EPS grew 418.2%, free cash flow fell 6.83% and total debt fell 42.2%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years.

72.54 0.02 +0.03%
Market cap
$11.4B
P/E
62.0×
Fwd P/E
37.6×
Dividend yield
0.44%
F-score
9/9
Altman Z
15.50
Beneish M
−2.52
Dividend safety
78/100

Bio-Techne Corp 10-K filed Aug 24, 2026

Fiscal year 2026 · Period ended Jun 30, 2026 · Filed · accepted 4:31 PM ET · Document on sec.gov · Filing index

What changed

Item 1A, Risk Factors, against the 10-K filed Aug 22, 2025: 28 added · 2 removed · 31 modified; 1 with only figures updated

61 more changes in this Item, word by word, in Powerpack.

Powerpack